UNSPSC 51111662: Uracil

This classification denotes a pyrimidine with the molecular formula C4H4N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 56HH86ZVCT, chemically known as 2,4-pyrimidinedione but generally known as uracil, which bears US NIH Compound Identifier 1174. European Medicines Agency schedules Uracil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20762. Most nations schedule uracil under HS 29335990 and SITC 51576. As of Q4 2014, URACIL remains the US FDA Preferred Term for this commodity.

Uracil bears US NLM identifiers UMLS ID C0041917 and NCI Concept Code C917. SMILES: O=C1[NH]C(=O)CC[NH]1.

UNSPSC 51111662 Uracil, a Commodity code, addresses pharmaceutical raw materials and active pharmaceutical ingredients sourced by state and local health agencies. State and local governments procure uracil and related pyrimidine compounds primarily through their health and human services departments and pharmacy benefit programs for use in compounded medications, cancer therapeutics, and metabolic disorder treatments. The issuing bodies for this code span state health departments, Medicaid agencies, state employee health plans, and county hospital systems that manage formulary procurement or specialty pharmacy operations. The work solicited under this code includes sourcing, qualification, and supply agreements for uracil as a finished pharmaceutical ingredient or bulk chemical precursor, often embedded within broader pharmacy benefit management or direct-to-manufacturer prescription programs where states seek to optimize drug acquisition costs and supply chain efficiency.

Recent activity shows the Texas Health and Human Services Commission issuing an RFI (Request for Information) on March 27, 2026, due April 3, 2026, for vendor capabilities supporting its Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. That RFI sought information on direct contracting strategies, pricing models, and supply fulfillment capacity outside traditional pharmacy benefit manager and group purchasing organization channels—a signal that state health agencies are exploring alternative procurement pathways for specialty pharmaceuticals and raw materials. Geographic concentration is limited; the source identifies only Texas HHS as an active issuing body in the recent-opportunities window, and no other states or jurisdictions appear in the dataset. The absence of broader geographic activity suggests either nascent or episodic procurement under this code, with uracil and similar APIs typically acquired through standing supply agreements or formulary-level contracts rather than frequent spot solicitations.